Cervical adenocarcinoma Trials in Las Vegas, United States
Conditions / Cervical adenocarcinoma / Las Vegas, United States
Cervical adenocarcinoma has been the subject of sustained clinical investigation across multiple research sites.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |